Cipher Pharmaceuticals reported disappointing second-quarter results, falling short of earnings estimates and facing challenges in revenue generation.
On August 10, 2026, Cipher Pharmaceuticals Inc (TSX: CPH) released its financial results for the second quarter of 2026, revealing a significant earnings miss. The company reported earnings per share (EPS) of $0.21, which was 19.2% below analysts' expectations of $0.26. This marks a notable deviation from the company's recent trend of outperforming earnings estimates, raising concerns among investors about future growth prospects.
Recent earnings trend
Advertisement
Cipher Pharmaceuticals Inc
CPH.TO
CPH.TO
Cipher Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$453.80M
P/E
10.8x
52W high
$20.56
52W low
$12.48
1W change
-16.61%
Beta
0.46
Analyst Price Targets
Based on analyst covering CPH
Wall Street analysts forecast CPH stock price to rise 46.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.64
+46.3% Upside
Current Price
C$14.11
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CPH's historical volatility
30-Day Vol
74.5%
Annualized
90-Day Vol
51.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$11.80
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$13.29 | C$10.28 – C$17.19 |
| 60 trading days | C$12.53 | C$8.71 – C$18.02 |
| 90 trading days | C$11.80 | C$7.56 – C$18.43 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 2 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-05 | — | 0.3200 | — |
| 2026-06-30 | 2026-08-10 | 0.2100 | 0.2600 | -19.2% |
| 2026-03-31 | 2026-05-07 | 0.3300 | 0.2200 | +50.0% |
| 2025-12-31 | 2026-03-12 | 0.6900 | 0.2100 | +228.6% |
| 2025-09-30 | 2025-11-06 | 0.3000 | 0.1700 | +76.5% |
| 2025-06-30 | 2025-08-07 | 0.3000 | 0.2200 | +36.4% |
Advertisement
Investor takeaway: Investors should closely monitor Cipher Pharmaceuticals' ability to stabilize its revenue and improve its earnings performance in upcoming quarters, especially given the company's historical success in surpassing expectations.
EPS Miss: 19.2% Below Estimates
Cipher Pharmaceuticals reported an EPS of $0.21 against estimates of $0.26, marking a significant earnings miss and a potential shift in investor sentiment.
Bull case
Cipher's leading product, Epuris®, has shown resilience with a 14% year-over-year revenue increase. The recent agreement with the pan-Canadian Pharmaceutical Alliance is expected to enhance patient access, which could drive future growth.
Bear case
The company's recent earnings miss and a 10% decline in total revenue indicate underlying challenges. Analysts may be cautious about Cipher's ability to maintain growth momentum, particularly in a competitive market.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
